Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP2A13 | Q16696 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18116866 | 0.82 | ALDH1A1 (0.37) | ALDH1A1SMN1; SMN2RECQLUSP2KDM4E | |
| SCHEMBL179555 | 0.80 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2RECQLUSP2KDM4E | |
| SCHEMBL20153265 | 0.79 | SMN1; SMN2 (0.50) | ALDH1A1SMN1; SMN2RECQLKDM4EKEAP1 | |
| SCHEMBL10153213 | 0.78 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2RECQLUSP2KDM4E | |
| SCHEMBL7281394 | 0.77 | CARM1 (0.33) | ALDH1A1SMN1; SMN2KDM4ETSHRLMNA | |
| SCHEMBL17310700 | 0.76 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2RECQLUSP2KDM4E | |
| SCHEMBL862113 | 0.76 | SMN1; SMN2 (0.41) | ALDH1A1SMN1; SMN2RECQLUSP2KDM4E | |
| SCHEMBL20623013 | 0.76 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2RECQLUSP2KDM4E | |
| SCHEMBL17392772 | 0.76 | SMN1; SMN2 (0.43) | ALDH1A1SMN1; SMN2RECQLUSP2KDM4E | |
| SCHEMBL6484208 | 0.76 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2RECQLUSP2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4374877-A2 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-29 | — | — | EP | disclosed |
| EP-3928779-B1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2024-03-06 | — | — | EP | disclosed |
| EP-3928779-A1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | Chugai Seiyaku Kabushiki Kaisha (JP) | 2021-12-29 | — | — | EP | disclosed |
| EP-3192511-B1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2021-07-14 | — | — | EP | disclosed |
| CN-107072993-B | Pharmaceutical containing sodium-dependent phosphate transporter inhibitor | 中外制药株式会社 | 2021-02-12 | — | — | CN | disclosed |
| EP-3757093-A1 | DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-12-30 | — | — | EP | disclosed |
| EP-2975030-B1 | DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2020-07-15 | — | — | EP | disclosed |
| US-10507209-B2 | Quinazoline derivatives substituted by aniline, preparation method and use thereof | XUANZHU PHARMA CO, LTD. (CN) | 2019-12-17 | — | — | US | disclosed |
| US-20170333433-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | XUANZHU PHARMA CO, LTD. (CN) | 2017-11-23 | — | — | US | disclosed |
| EP-3192511-A1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR | Chugai Seiyaku Kabushiki Kaisha (JP) | 2017-07-19 | — | — | EP | disclosed |
| US-20170029469-A1 | CYCLOSPORIN ANALOGS | ALLERGAN, INC. | 2017-02-02 | — | — | US | disclosed |
| US-9499553-B2 | Dihydropyridazine-3,5-dione derivative and pharmaceuticals containing the same | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-22 | — | — | US | disclosed |
| US-9493511-B2 | Cyclosporin analogs | ALLERGAN, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-9493511-B2 | Cyclosporin analogs | ALLERGAN, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| EP-2975030-A1 | DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2016-01-20 | — | — | EP | disclosed |
| US-20160002251-A1 | DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE AND PHARMACEUTICALS CONTAINING THE SAME | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-01-07 | — | — | US | disclosed |
| US-20150065433-A1 | CYCLOSPORIN ANALOGS | ALLERGAN, INC. (US) | 2015-03-05 | — | — | US | disclosed |
| US-20150065433-A1 | CYCLOSPORIN ANALOGS | ALLERGAN, INC. (US) | 2015-03-05 | — | — | US | disclosed |
| US-20120088734-A1 | Cyclosporin Analogs | ALLERGAN, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-20120088734-A1 | Cyclosporin Analogs | ALLERGAN, INC. (US) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065433-A1 | CYCLOSPORIN ANALOGS | CHP1, TSLP, PPP3R1 | ALDH1A1 4113/4885SMN1; SMN2 4747/4885RECQL 2251/4885 |
| US-20170333433-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | NQO2, CHRM1, CHRM2 | ALDH1A1 691/4885SMN1; SMN2 4480/4885RECQL 313/4885 |
| US-20120088734-A1 | Cyclosporin Analogs | CHP1, TSLP, PPP3R1 | ALDH1A1 4113/4885SMN1; SMN2 4747/4885RECQL 2251/4885 |
| US-20170029469-A1 | CYCLOSPORIN ANALOGS | CHP1, TSLP, PPP3R1 | ALDH1A1 4113/4885SMN1; SMN2 4747/4885RECQL 2251/4885 |
| US-20160002251-A1 | DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE AND PHARMACEUTICALS CONTAINING THE SAME | SLC9A5, SLC5A2, SLC5A1 | ALDH1A1 2320/4885SMN1; SMN2 4838/4885RECQL 3779/4885 |
| US-10507209-B2 | Quinazoline derivatives substituted by aniline, preparation method and use thereof | NQO2, CHRM1, CHRM2 | ALDH1A1 691/4885SMN1; SMN2 4480/4885RECQL 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.